1. Naturally Sourced CDK Inhibitors and Current Trends in Structure-Based Synthetic Anticancer Drug Design by Crystallography
   Sisir Nandi et al, 2022, Anti-Cancer Agents in Medicinal Chemistry CrossRef
2. Flavopiridol Sensitivity of Cancer Cells Isolated from Ascites and Pleural Fluids
   Christina Richard et al, 2005, Clinical Cancer Research CrossRef
3. Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid Tumors
   Gary K. Schwartz et al, 2002, Journal of Clinical Oncology CrossRef
4. Successful Treatment of Animal Models of Rheumatoid Arthritis with Small-Molecule Cyclin-Dependent Kinase Inhibitors
   Chiyoko Sekine et al, 2008, The Journal of Immunology CrossRef
5. CytochromeP450 Epoxygenase Promotes Human Cancer Metastasis
   Jian-Gang Jiang et al, 2007, Cancer Research CrossRef
6. A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer
   Glenn Liu et al, 2004, Clinical Cancer Research CrossRef
7. Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents
   Ian N. Fleming et al, 2008, Clinical Cancer Research CrossRef
8. Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer
   Antoinette R. Tan et al, 2004, Clinical Cancer Research CrossRef
9. Retinoblastoma Tumor Suppressor Gene Expression Determines the Response to Sequential Flavopiridol and Doxorubicin Treatment in Small-Cell Lung Carcinoma
   Tulin Budak-Alpdogan et al, 2009, Clinical Cancer Research CrossRef